Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.

Show other versions (1)

OBJECTIVES: Reports have suggested that a reduction in tumour 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) examination during or after neoadjuvant chemotherapy may predict pathological response in oesophageal cancer. Our aim was to determine whether metabolic response pr...

Full description

Bibliographic Details
Main Authors:	Gillies, R, Middleton, MR, Blesing, C, Patel, K, Warner, N, Marshall, R, Maynard, N, Bradley, K, Gleeson, F
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer
by: Gillies, R, et al.
Published: (2012)

Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics.
by: Findlay, J, et al.
Published: (2017)

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
by: Gillies, R, et al.
Published: (2012)

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma
by: Gillies, R, et al.
Published: (2012)

Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
by: Findlay, J, et al.
Published: (2017)

Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer
by: Gillies, R, et al.
Published: (2011)

Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
by: Gillies, R, et al.
Published: (2011)

Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer
by: Gillies, R, et al.
Published: (2010)

Predicting pathological response of esophageal cancer to neoadjuvant chemotherapy: the implications of metabolic nodal response for personalised therapy
by: Findlay, J, et al.
Published: (2016)

Role of adjuvant radiotherapy following neo-adjuvant chemotherapy (NACT) and surgery in oesophageal cancer - a multi-centre retrospective cohort study
by: Teoh, S, et al.
Published: (2016)

The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.
by: Chowdhury, F, et al.
Published: (2008)

Neoadjuvant chemotherapy for oesophageal carcinoma - a risk factor for postoperative pneumonia?
by: Millo, J, et al.
Published: (2003)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
by: Findlay, J, et al.
Published: (2016)

Survival after curative chemoradiotherapy or neoadjuvant therapy and surgery converges in higher-risk patients with oesophageal cancer
by: Rana, M, et al.
Published: (2021)

Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer
by: den Boer, RB, et al.
Published: (2020)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
by: John M. Findlay, et al.
Published: (2016-04-01)

A reply to evidence-based radiation oncology: oesophagus.
by: Gillies, R, et al.
Published: (2010)

A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
by: Kieran G. Foley, et al.
Published: (2021-06-01)

Adjuvant radiotherapy following neo-adjuvant chemotherapy and surgery in oesophageal cancer: a retrospective cohort study of survival
by: Teoh, S, et al.
Published: (2018)

Assessment of Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Using MRI and 18F FDG PET/CT
by: Reem Yusuf AlBuainain, et al.
Published: (2025-01-01)

Role of F-18 FDG PET/CT in Predicting Response to Neoadjuvant Chemotherapy in Invasive Ductal Breast Cancer
by: Tarik Sengoz, et al.
Published: (2023-04-01)

PET/CT staging and response evaluation of post-transplantation lymphoproliferative disease (PTLD).
by: Chowdhury, F, et al.
Published: (2009)

Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy
by: A. G. M. T. Powell, et al.
Published: (2020-08-01)

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
by: Alexander M Th Schmitz, et al.
Published: (2017-01-01)

Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis
by: Lihua Chen, et al.
Published: (2017-08-01)

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
by: Turkington, RC, et al.
Published: (2019)

Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery
by: Findlay, J, et al.
Published: (2019)

Clinical value of SUVpeak-to-tumor centroid distance on FDG PET/CT for predicting neoadjuvant chemotherapy response in patients with breast cancer
by: Sun-pyo Hong, et al.
Published: (2024-10-01)

Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy
by: M. K. Ibragimova, et al.
Published: (2022-03-01)

Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis
by: Sangwon Han, et al.
Published: (2020-10-01)

Efficacy Of 18FDG-PET/CT In Predicting Response After Neoadjuvant Chemoradiation In Rectal Cancer
by: Narendra Pandit, et al.
Published: (2023-08-01)

Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancer
by: Inci Kizildag Yirgin, et al.
Published: (2020-01-01)

The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
by: Yao J, et al.
Published: (2021-10-01)

Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy. Additional material
by: M. K. Ibragimova, et al.
Published: (2022-03-01)

Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
by: Rui-Qin Zhou, et al.
Published: (2023-05-01)

[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
by: Giulia Polverari, et al.
Published: (2020-10-01)

Correlation Between 18F-FDG PET/CT SUVmax and Clinicopathological Features, Neoadjuvant Chemotherapy Response in Invasive Ductal Breast Carcinoma Patients
by: LU Shengnan, et al.
Published: (2019-02-01)

Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
by: Willard Wong, et al.
Published: (2021-07-01)

EVALUATİON OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY İN PATİENTS WİTH BREAST CANCER
by: Can Atalay, et al.
Published: (2007-01-01)

MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS
by: P. V. Kazantseva, et al.
Published: (2016-07-01)